# US 11,077,053 B2 · Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,077,053 B2
- Document ID: US11077053B2
- Status: Granted
- Kind: B2
- Application number: 16/950,574
- Filed: 2020-11-17
- Published: 2021-03-04
- Granted: 2021-08-03
- Earliest claimed: 2018-08-21
- Assignees: Allergan, Inc.
- Applicants: Allergan, Inc.
- Inventors: Mohammed Dibas; Daniel W. Gil; Wayne Chen; Miguel Alcantara
- Web page: https://patentgrep.com/patent/US11077053B2

## CPC

- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 31/4178: not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A61P 27/02: Ophthalmic agents
- A61P 27/10: for accommodation disorders, e.g. myopia
- A61K 9/0051: {Ocular inserts or implants}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods of using the alpha-2-adrenergic receptor agonist of Formula I: for improving vision such as in the treatment of ocular conditions such as presbyopia, poor night vision, visual glare, visual starbursts, visual halos, and some forms of myopia (e.g. night myopia) are described.

## Claims

### Claim 1

A method of treating an ocular condition in an individual in need of such treatment, the method comprising administering to the individual a therapeutically effective amount of a compound of Formula I:
or a pharmaceutically acceptable salt thereof; wherein the ocular condition is selected from the group consisting of presbyopia, visual glare, visual starbursts, visual halos, and night myopia; wherein the therapeutically effective amount of the compound of Formula I or pharmaceutically acceptable salt thereof is administered topically to one or both eyes of the individual as a pharmaceutically acceptable composition comprising the therapeutically effective amount of the compound of Formula I or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient; and wherein the pharmaceutically acceptable composition comprises the compound of Formula I in an amount of from 0.01% (w/v) to 0.3% (w/v).

### Claim 2 (depends on 1)

The method of claim 1, wherein the ocular condition is presbyopia.

### Claim 3 (depends on 1)

The method of claim 1, wherein the ocular condition is visual glare.

### Claim 4 (depends on 1)

The method of claim 1, wherein the ocular condition is visual starbursts.

### Claim 5 (depends on 1)

The method of claim 1, wherein the ocular condition is visual halos.

### Claim 6 (depends on 1)

The method of claim 1, wherein the ocular condition is night myopia.

### Claim 7 (depends on 1)

The method of claim 1, wherein the pharmaceutically acceptable composition comprises the compound of Formula I in an amount of 0.01% (w/v).

### Claim 8 (depends on 1)

The method of claim 1, wherein the pharmaceutically acceptable composition comprises the compound of Formula I in an amount of 0.03% (w/v).

### Claim 9 (depends on 1)

The method of claim 1, wherein the pharmaceutically acceptable composition comprises the compound of Formula I in an amount of 0.1% (w/v).

### Claim 10 (depends on 1)

The method of claim 1, wherein the pharmaceutically acceptable composition comprises the compound of Formula I in an amount of 0.3% (w/v).

### Claim 11 (depends on 1)

The method of claim 1, wherein the method comprises administering a pharmaceutically acceptable salt of compound 1 and wherein the pharmaceutically acceptable salt is a hydrochloride salt.